Diffuse Large B-Cell Lymphoma Clinical Trials

A listing of 35 Diffuse Large B-Cell Lymphoma clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.

Home

All Conditions

Diffuse Large B-Cell Lymphoma

1 - 12 of 35

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

There are currently 35 active clinical trials seeking participants for Diffuse Large B-Cell Lymphoma research studies. The states with the highest number of trials for Diffuse Large B-Cell Lymphoma participants are California, New York, Ohio and Texas.

Featured Trial

Paid Clinical Studies Nationwide

Recruiting

Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.

Conditions:

Healthy

Healthy Volunteer Study

Learn More

* Compensation for time may be available

Featured Trial

Chronic Cough Research Study

Recruiting

Are you tired of living with chronic cough? Our research study is now looking to enroll people from all backgrounds to help research potential new treatment options for chronic cough.
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!

Conditions:

Chronic Cough

Refractory or Unexplained Chronic Cough

Cough

Asthma

Sinusitis

Learn More

Featured Trial

Type 2 Diabetes Clinical Trial

Recruiting

Can changing your breakfast improve your type 2 diabetes? If you have an HbA1C of 7.0% or higher, you are invited to participate in an online study at the University of Michigan.

Conditions:

Type 2 Diabetes

Diabetes Mellitus Type 2 in Obese

Diabetes Type Two

Type 2 Diabetes Mellitus

Diabete Type 2

Learn More

Featured Trial

Crohn's Disease Clinical Study

Recruiting

Help us study a potential new way to treat Crohn's disease. We are seeking adults living with Crohn's disease to join our latest clinical trial to help us learn more. Eligible participants will receive study-related treatment, assessments, and care at no cost. You will also receive reimbursement for travel while participating. Health insurance is not required to take part.

Conditions:

Crohn's Disease

Crohn Disease

Crohns Disease

Crohn's Disease (CD)

Crohn Colitis

Learn More

Pharmacogenomics Effects on High-Dose Methotrexate Clearance in Patients With Diffuse Large B-Cell Lymphoma

NCT06031194

Recruiting

This study evaluates pharmacogenomic effects on high-dose methotrexate clearance in patients with diffuse large B-cell lymphoma.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

04/25/2025

Locations: Ohio State University Comprehensive Cancer Center, Columbus, Ohio

Conditions: Central Nervous System Lymphoma, Diffuse Large B-Cell Lymphoma

Learn More ›

Zanubrutinib in Combination with R-PolaCHP (ZaR-PolaCHP) for Newly Diagnosed Diffuse Large B-Cell Lymphoma

NCT04850495

Recruiting

This phase Ib trial seeks to find out the best dose and possible side effects and/or benefits of zanubrutinib in combination with the R-PolaCHP in treating patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL). Zanubrutinib is designed to block a protein called Bruton Tyrosine Kinase in order to stop cancer growth. R-CHOP is the acronym for the combination of five drugs: rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone. It is the most widely used chemoimmunother... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/21/2025

Locations: Ohio State University Comprehensive Cancer Center, Columbus, Ohio +1 locations

Conditions: Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma

Learn More ›

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma

NCT03223610

Recruiting

Background: B-cell lymphoma is a cancer of white blood cells found in the lymph nodes. It affects the system that fights infections and disease. Researchers want to learn how certain drugs work together to treat B-cell lymphomas. The drugs are venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide (ViPOR). Objective: To study the safety of ViPOR for people with B-cell lymphoma. Eligibility: People ages 18 and older with B-cell lymphoma whose cancer has returned or not improved af... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

06/04/2025

Locations: National Institutes of Health Clinical Center, Bethesda, Maryland

Conditions: Lymphoma, Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, Burkitt Lymphoma

Learn More ›

Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma

NCT04002947

Recruiting

Background: Diffuse large B-cell lymphoma is the most common type of non-Hodgkin lymphoma. Most people with this cancer can be cured. But those who are not cured have a poor prognosis. Researchers want to add another drug to standard treatment see if it can improve the cure rate. Objective: To see if the drug acalabrutinib given with rituximab and standard combination chemotherapy can improve the cure rate of aggressive B-cell lymphomas such as diffuse large B-cell lymphoma. Eligibility: Pe... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

06/03/2025

Locations: National Institutes of Health Clinical Center, Bethesda, Maryland

Conditions: Diffuse Large B-Cell Lymphoma, DLBCL, NHL, Non-Hodgkin's Lymphoma

Learn More ›

Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma

NCT05660967

Recruiting

The purpose of the study is to examine efficacy and safety of epcoritamab with and without lenalidomide in newly diagnosed elderly patients with Diffuse Large B-Cell Lymphoma (DLBCL) who cannot tolerate anthracycline therapy. Epcoritamab (also known as EPKINLY™, GEN3013 and DuoBody®-CD3xCD20) is an antibody that has already been tested in several clinical studies. All patients will receive active treatment. There is an equal chance of receiving epcoritamab or epcoritamab plus lenalidomide.

Gender:

ALL

Ages:

75 years and above

Trial Updated:

06/02/2025

Locations: UW Cancer Center at ProHealth Care, Waukesha, Wisconsin +77 locations

UW Cancer Center at ProHealth Care, Waukesha, Wisconsin

Kepler Universitätsklinikum, Linz, Not set

LKH - Universitätsklinikum der PMU Salzburg, Salzburg, Not set

Klinikum Wels-Grieskirchen GmbH, Wels, Not set

Institut Jules Bordet, Anderlecht, Not set

GZA Ziekenhuizen, Antwerpen, Not set

ZNA, Antwerpen, Not set

UZ Brussels, Jette, Not set

UZ Leuven, Leuven, Not set

AZ Delta, Roeselare, Not set

Vitaz, Temse, Not set

AZ Turnhout - Campus Sint-Elisabeth, Turnhout, Not set

Fakultni nemocnice Hradec Kralove, Hradec Králové, Not set

Vseobecna fakultni nemocnice v Praze, Praha 2, Not set

Fakultni nemocnice v Motole, Praha 5, Not set

CHU Angers - Hôpital Hôtel Dieu, Angers, Not set

Hôpital Henri Mondor, Créteil, Not set

Hopital Claude Huriez - CHRU Lille, Lille, Not set

Hopital de la Conception - APHM, Marseille, Not set

CHU de Nantes - Hotel Dieu, Nantes, Not set

Centre Antoine Lacassagne, Nice, Not set

Hôpital Saint-Antoine, Paris, Not set

Hôpital Saint-Louis, Paris, Not set

CHU de Bordeaux - Hôpital Haut-Lévêque, Pessac, Not set

CHU Amiens - Hopital Sud, Salouël, Not set

CHU Tours - Hôpital Bretonneau, Tours, Not set

Universitaetsklinikum Freiburg, Freiburg, Baden Wuerttemberg

Universitaetsklinikum Aachen AOeR, Aachen, Not set

Vivantes Klinikum Neukoelln, Berlin, Not set

Universitaetsklinikum Wuerzburg, Würzburg, Not set

Clinica di Ematologia AOU Ospedali Riuniti di Ancona, Ancona, Not set

IRCCS Centro di Riferimento Oncologico, Aviano, Not set

Azienda Ospedaliera Universitaria Policlinico Sant'Orsola Malpighi IRCCS, Bologna, Not set

Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (Presidio Spedali Civili), Brescia, Not set

Fondazione del Piemonte per l'Oncologia IRCC Candiolo, Candiolo, Not set

IRCCS Istituto Romagnolo Per Lo Studio Dei Tumori "Dino Amadori" - IRST, Meldola, Not set

IEO Istituto Europeo di Oncologia Parent, Milano, Not set

Ospedale San Raffaele, Milano, Not set

Azienda Ospedaliera Vincenzo Cervello, Palermo, Not set

AUSL Piacenza Ospedale Guglielmo da Saliceto, Piacenza, Not set

Azienda sanitaria integrata università di Trieste, Trieste, Not set

Kyushu University Hospital, Fukuoka shi, Not set

Kagoshima University Hospital, Kagoshima, Not set

Kanazawa University Hospital, Kanazawa, Not set

National Cancer Center Hospital East, Kashiwa, Not set

Cancer Institute Hospital of JFCR, Koto-Ku, Not set

Matsuyama Red Cross Hospital, Matsuyama, Not set

NHO Nagoya Medical Center, Nagoya shi, Not set

Yamagata University Hospital, Yamagata, Not set

Kindai University Hospital, Ōsaka-sayama, Not set

Keimyung University Dongsan Hospital, Daegu, Not set

National Cancer Center, Goyang-si, Not set

Jeonbuk National University Hospital, Jeonju, Not set

Asan Medical Center, Seoul, Not set

Samsung Medical Center, Seoul, Not set

Seoul National University Hospital, Seoul, Not set

Wojewodzki Szpital Specjalistyczny w Bialej Podlaskiej, Biała Podlaska, Not set

Pratia MCM Krakow, Kraków, Not set

Centrum Medyczne Pratia Poznan, Skorzewo, Not set

MICS Centrum Medyczne Torun, Toruń, Not set

ICO Badalona - Hospital Universitari Germans Trias i Pujol, Badalona, Not set

Hospital Clinic de Barcelona, Barcelona, Not set

ICO l'Hospitalet - Hospital Duran i Reynals, Barcelona, Not set

Hospital San Pedro de Alcantara, Cáceres, Not set

Hospital General Universitario Gregorio Marañon, Madrid, Not set

Hospital Universitario 12 de Octubre, Madrid, Not set

Hospital Universitario Fundacion Jimenez Diaz, Madrid, Not set

Hospital Universitario Ramon y Cajal, Madrid, Not set

Hospital Universitario Nuestra Señora de Valme, Sevilla, Not set

Hospital Universitario Puerta del Mar, Sevilla, Not set

Hospital Universitario Virgen Macarena, Sevilla, Not set

Bristol Haematology and Oncology Centre, Bristol, Not set

Royal Marsden Hospital - Fulham, London, Not set

Churchill Hospital, Oxford, Not set

Derriford Hospital, Plymouth, Not set

Southampton General Hospital, Southampton, Not set

Royal Marsden Hospital, Sutton, Not set

Royal Cornwall Hospital NHS Trust, Truro, Not set

Conditions: Diffuse Large B-Cell Lymphoma

Learn More ›

A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

NCT06508658

Recruiting

B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections). This study will assess how safe and effective epcoritamab plus lenalidomide (E-Len) is compared to rituximab plus gemcitabine and oxaliplatin (R-GemOx) )in treating adult participants with relapsed or refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL). Adverse events and change in disease condition will be assessed. Epcoritamab is an investigational drug being... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

06/02/2025

Locations: Valkyrie Clinical Trials /ID# 269935, Los Angeles, California +142 locations

Valkyrie Clinical Trials /ID# 269935, Los Angeles, California

Lutheran Medical Center- Cancer Centers of Colorado /ID# 265823, Golden, Colorado

Northwest Cancer Center - Dyer Clinic /ID# 269787, Dyer, Indiana

Cancer Center of Kansas - Wichita /ID# 270117, Wichita, Kansas

University of Kentucky Chandler Medical Center /ID# 242087, Lexington, Kentucky

University of Maryland, Baltimore /ID# 242216, Baltimore, Maryland

Gulfport Memorial Hospital /ID# 268104, Gulfport, Mississippi

New York Medical College /ID# 265799, Valhalla, New York

Thompson Cancer Survival Ctr /ID# 242149, Knoxville, Tennessee

Community Cancer Trials Of Utah /ID# 271715, Ogden, Utah

Utah Cancer Specialists - Salt Lake City /ID# 268603, Salt Lake City, Utah

Veterans Affairs Medical Center - Salt Lake City /ID# 265329, Salt Lake City, Utah

Canberra Hospital /ID# 265312, Canberra, Australian Capital Territory

Royal Prince Alfred Hospital /ID# 263242, Sydney, New South Wales

Wollongong Hospital /ID# 244646, Wollongong, New South Wales

Toowoomba Hospital /ID# 263243, Toowoomba, Queensland

Monash Health - Monash Medical Centre /ID# 262783, Clayton, Victoria

Royal Perth Hospital /ID# 243790, Perth, Western Australia

Universitair Ziekenhuis Brussel /ID# 242574, Jette, Bruxelles-Capitale

Centre Hospitalier Epicura - site d'Hornu /ID# 265148, Boussu, Hainaut

Université Catholique de Louvain-Namur - Centre Hospitalier Universitaire Dinant /ID# 242565, Yvoir, Namur

Universitair Ziekenhuis Leuven /ID# 246671, Leuven, Vlaams-Brabant

AZ-Delta /ID# 264740, Roeselare, West-Vlaanderen

UMHAT Sveti Georgi /ID# 242905, Plovdiv, Not set

UMHAT Sveti Ivan Rilski /ID# 242389, Sofia, Not set

SHAT Hematologic Diseases /ID# 242708, Sofia, Not set

UMHAT Sveta Marina /ID# 262761, Varna, Not set

CIUSSS de l'est de l'Ile-de-Montreal - Hopital Maisonneuve-Rosemont /ID# 262751, Montreal, Quebec

Peking University Third Hospital /ID# 242941, Beijing, Beijing

Fujian Province Cancer Hospital /ID# 265075, Fuzhou, Fujian

The First Affiliated Hospital of Xiamen /ID# 264305, Xiamen, Fujian

Sun Yat-Sen University Cancer Center /ID# 242712, Guangzhou, Guangdong

Guangdong Provincial People's Hospital /ID# 242942, Guangzhou, Guangdong

The Second Hospital of Hebei Medical University /ID# 242944, Shijiazhuang, Hebei

Harbin Medical University Cancer Hospital /Id# 242961, Harbin, Heilongjiang

Henan Cancer Hospital /ID# 242700, Zhengzhou, Henan

Union Hospital affiliated to Tongji Medical College of Huazhong University of Sc /ID# 242702, Wuhan, Hubei

Hubei Cancer Hospital /ID# 242963, Wuhan, Hubei

The First Affiliated Hospital of Soochow University /ID# 242939, Suzhou, Jiangsu

The First Affiliated Hospital of Nanchang University /ID# 242703, Nanchang, Jiangxi

Jiangxi Provincial Cancer Hospital /ID# 242968, Nanchang, Jiangxi

The First Hospital of Jilin University /ID# 242940, Changchun, Jilin

The First Hospital of China Medical University /ID# 242701, Shenyang, Liaoning

Shandong Cancer Hospital /ID# 264036, Jinan, Shandong

Shanghai Tongji Hospital /ID# 263952, Shanghai, Shanghai

Tianjin Cancer Hospital /ID# 243940, Tianjin, Tianjin

Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sc /ID# 243139, Tianjin, Tianjin

The Affiliated Cancer Hospital of Xinjiang Medical University /ID# 242966, Urumqi, Xinjiang

The First Affiliated Hospital, Zhejiang University School of Medicine /ID# 242960, Hangzhou, Zhejiang

The second affiliated hospital of Zhejiang University school of medicine /ID# 243137, Hangzhou, Zhejiang

Zhejiang Cancer hospital /ID# 242711, Hangzhou, Zhejiang

The First Affiliated Hospital of Wenzhou Medical University /ID# 263951, Wenzhou, Zhejiang

Klinicka bolnica Merkur /ID# 262619, Zagreb, Grad Zagreb

Klinicki bolnicki centar Sestre milosrdnice /ID# 262620, Zagreb, Grad Zagreb

Klinicki bolnicki centar Zagreb /ID# 262617, Zagreb, Grad Zagreb

Klinicki bolnicki centar Osijek /ID# 262621, Osijek, Osjecko-baranjska Zupanija

Klinički Bolnički Centar Rijeka /ID# 266004, Rijeka, Primorsko-goranska Zupanija

Klinicki Bolnicki Centar (KBC) Split /ID# 262618, Split, Splitsko-dalmatinska Zupanija

Fakultní nemocnice Hradec Králové - Sokolská /ID# 264071, Hradec Králové, Hradec Kralove

CHRU Tours - Hopital Bretonneau /ID# 244580, Tours CEDEX 9, Indre-et-Loire

Centre Hospitalier D'Avignon /ID# 243072, Avignon, Provence-Alpes-Cote-d Azur

Centre Hospitalier de la Cote Basque /ID# 243065, Bayonne, Pyrenees-Atlantiques

CHU Poitiers - La miletrie /ID# 243074, Poitiers, Vienne

CHU de CAEN - Hopital de la Cote de Nacre /ID# 243075, Caen, Not set

Hopital Saint Vincent de Paul /ID# 243070, Lille Cedex, Not set

Institut de cancérologie Strasbourg Europe (ICANS) /ID# 264068, Strasbourg, Not set

General Hospital of Athens Laiko /ID# 262809, Athens, Attiki

University General Hospital Attikon /ID# 242041, Athens, Attiki

General Hospital of Athens Evaggelismos and Ophthalmiatrio of Athens Polyclinic /ID# 242039, Athens, Not set

General University Hospital of Thessaloniki AXEPA /ID# 242038, Thessaloniki, Not set

Theageneio Anticancer Hospital /ID# 242036, Thessaloniki, Not set

Pecsi Tudomanyegyetem Klinikai Kozpont /ID# 262924, Pecs, Baranya

Gyor-Moson-Sopron Varmegyei Petz Aladar Egyetemi Oktato Korhaz /ID# 262901, Gyor, Gyor-Moson-Sopron

Debreceni Egyetem-Klinikai Kozpont /ID# 242451, Debrecen, Hajdu-Bihar

Szabolcs-Szatmar-Bereg Varmegyei Oktatokorhaz /ID# 242468, Nyiregyhaza, Szabolcs-Szatmar-Bereg

Semmelweis Egyetem /ID# 242455, Budapest, Not set

Del-pesti Centrumkorhaz Orszagos Hematologiai es Infektologiai Intezet /ID# 262923, Budapest, Not set

Orszagos Onkologiai Intezet /ID# 242457, Budapest, Not set

Fujita Health University Hospital /ID# 265968, Toyoake, Aichi

National Hospital Organization Shikoku Cancer Center /ID# 265977, Matsuyama, Ehime

Kyushu University Hospital /ID# 267624, Fukuoka-shi, Fukuoka

Fukushima Medical University Hospital /ID# 264667, Fukushima-shi, Fukushima

Sapporo Medical University Hospital /ID# 264928, Sapporo, Hokkaido

Kagoshima University Hospital /ID# 248259, Kagoshima-shi, Kagoshima

Tokai University Hospital /ID# 265433, Isehara, Kanagawa

Kansai Medical University Hospital /ID# 266018, Hirakata-shi, Osaka

Kindai University Hospital /ID# 265474, Osakasayama-shi, Osaka

Saitama Cancer Center /ID# 265277, Kitaadachi-gun, Saitama

University of Yamanashi Hospital /ID# 264671, Chuo, Yamanashi

Inje University - Busan Paik Hospital /ID# 262842, Busan, Busan Gwang Yeogsi

Dong-A University Medical Center /ID# 262841, Busan, Busan Gwang Yeogsi

Seoul National University Bundang Hospital /ID# 242405, Seongnam-si, Gyeonggido

Keimyung University Dongsan Hospital /ID# 262840, Daegu, Gyeongsangbugdo

Jeonbuk National University Hospital /ID# 242958, Jeonju, Jeonrabugdo

Chonnam National University Hwasun Hospital /ID# 262843, Hwasun-gun, Jeonranamdo

Seoul National University Hospital /ID# 242407, Seoul, Seoul Teugbyeolsi

Asan Medical Center /ID# 242409, Seoul, Seoul Teugbyeolsi

Samsung Medical Center /ID# 242408, Seoul, Seoul Teugbyeolsi

The Catholic University of Korea, Seoul St. Marys Hospital /ID# 242406, Seoul, Seoul Teugbyeolsi

Ulsan University Hospital /ID# 242956, Ulsan, Ulsan Gwang Yeogsi

Medisch Centrum Leeuwarden /ID# 245501, Leeuwarden, Friesland

Jeroen Bosch Ziekenhuis, locatie 's-Hertogenbosch /ID# 265204, 's-Hertogenbosch, Noord-Brabant

OLVG - Locatie Oost /ID# 263355, Amsterdam, Noord-Holland

St. Antonius Ziekenhuis /ID# 245197, Nieuwegein, Utrecht

Albert Schweitzer Ziekenhuis, locatie Dordwijk /ID# 263361, Dordrecht, Zuid-Holland

North Shore Hospital /ID# 266060, Auckland, Not set

Wellington Hospital /ID# 265966, Wellington, Not set

Pratia MCM Krakow /ID# 262882, Krakow, Malopolskie

Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie Panstwowy Instytut Bada /ID# 263314, Warsaw, Mazowieckie

Swietokrzyskie Centrum Onkologii Samodzielny Publiczny Zaklad Opieki Zdrowotnej /ID# 242436, Kielce, Swietokrzyskie

Aidport sp z o.o. /ID# 262766, Poznan, Wielkopolskie

Hospital da Luz /ID# 262965, Lisbon, Lisboa

Instituto Portugues de Oncologia do Porto Francisco Gentil, EPE /ID# 262961, Porto, Not set

Unidade Local de Saude de Sao Joao, EPE /ID# 262962, Porto, Not set

Fundeni Clinical Institute /ID# 266734, Bucharest, Bucuresti

Institutul Oncologic Prof Dr I Chiricuta /ID# 243753, Cluj Napoca, Cluj

Institutul Regional de Oncologie /ID# 244367, Jassi, Iasi

Spitalul Clinic Coltea /ID# 243694, Bucharest, Not set

Clinical Hospital Center Zvezdara /ID# 263059, Belgrade, Beograd

Institute for Oncology and Radiology of Serbia /ID# 263055, Belgrade, Beograd

University Clinical Center Serbia /ID# 263057, Belgrade, Beograd

Clinical Hospital Center - Bežanijska Kosa /ID# 263053, Belgrade, Beograd

University Clinical Center Nis /ID# 263701, Niš, Nisavski Okrug

Institute for Oncology of Vojvodina /ID# 263052, Sremska Kamenica, Vojvodina

University Clinical Center Vojvodina /ID# 264138, Novi Sad, Not set

National Cancer Centre Singapore /ID# 267015, Singapore, Central Singapore

National University Hospital /ID# 264016, Singapore, Not set

Tan Tock Seng Hospital /ID# 266061, Singapore, Not set

Wits Clinical Research /ID# 264656, Johannesburg, Gauteng

Alberts Cellular Therapy /ID# 262720, Pretoria, Gauteng

Haemalife Inc. /ID# 262719, Kuilsrivier, Western Cape

National Taiwan University Hospital /ID# 243300, Taipei City, Taipei

China Medical University Hospital /ID# 242931, Taichung, Not set

Taichung Veterans General Hospital /ID# 242937, Taichung, Not set

National Cheng Kung University Hospital /ID# 243301, Tainan, Not set

Ankara Universitesi Fakultesi /ID# 242410, Ankara, Not set

Adnan Menderes University /ID# 242418, Aydin, Not set

Trakya University Medical Facu /ID# 242419, Edirne, Istanbul, Not set

Ondokuz mayis University Facul /ID# 242412, Samsun, Not set

Karadeniz Technical University Farabi Hospital /ID# 264694, Trabzon, Not set

Istanbul Florence Nightingale Hospital /ID# 271544, Şişli, Not set

Nottingham City Hospital /ID# 265129, Nottingham, Nottinghamshire

The Newcastle Upon Tyne Hospitals NHS Foundation Trust /ID# 242923, Newcastle upon Tyne, Not set

Conditions: Diffuse Large B-Cell Lymphoma

Learn More ›

A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)

NCT05512390

Recruiting

B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections). Follicular Lymphoma is a slow-growing type of non-Hodgkin lymphoma. Chronic lymphocytic leukemia (CLL) is the most common leukemia (cancer of blood cells). The purpose of this study is to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of ABBV-319 in adult participants in relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL)... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/30/2025

Locations: University of Arizona Cancer Center - Tucson /ID# 247752, Tucson, Arizona +14 locations

Conditions: Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia, Follicular Lymphoma

Learn More ›

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)

NCT05139017

Recruiting

The purpose of this Phase 2/3, randomized, multisite, open-label, dose confirmation, and expansion study is to evaluate the safety, and efficacy of zilovertamab vedotin (ZV) in combination with standard of care options for the treatment of rrDLBCL. This study will be divided into 2 parts: Dose Confirmation (Part 1) and Efficacy Expansion (Part 2) and will enroll participants who are at least 18 years of age with rrDLBCL. The hypotheses are: ZV in combination with rituximab, gemcitabine, and oxal... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/28/2025

Locations: Bass Medical Group ( Site 0166), Walnut Creek, California +100 locations

Bass Medical Group ( Site 0166), Walnut Creek, California

Innovative Clinical Research Institute ( Site 0122), Whittier, California

Boca Raton Regional Hospital- Lynn Cancer Institute ( Site 0163), Boca Raton, Florida

Saint Elizabeth Medical Center Edgewood ( Site 0165), Edgewood, Kentucky

University of Kentucky Chandler Medical Center ( Site 0158), Lexington, Kentucky

Norton Women's and Children's Hospital-Norton Cancer Institute - St. Matthews ( Site 0133), Louisville, Kentucky

Louisiana State University Health Sciences Center New Orleans ( Site 0134), New Orleans, Louisiana

University of Maryland ( Site 0123), Baltimore, Maryland

Dana-Farber Cancer Institute-Lymphoma ( Site 0111), Boston, Massachusetts

University of Massachusetts Medical School ( Site 0119), Worcester, Massachusetts

St. Vincent Frontier Cancer Center-Research ( Site 0108), Billings, Montana

Atlantic Health System ( Site 0116), Morristown, New Jersey

New York Medical College ( Site 0113), Valhalla, New York

Vanderbilt University Medical Center-Vanderbilt-Ingram Cancer Center ( Site 0156), Nashville, Tennessee

Hospital Italiano de Buenos Aires ( Site 2203), Ciudad Autonoma de Buenos Aires, Buenos Aires

Instituto de Investigaciones Clínicas Mar del Plata ( Site 2205), Mar del Plata., Buenos Aires

Hospital Aleman ( Site 2200), Buenos Aites, Caba

Instituto Alexander Fleming ( Site 2201), Caba, Not set

Hospital Privado Universitario de Córdoba ( Site 2202), Cordoba, Not set

Townsville University Hospital ( Site 1800), Douglas, Queensland

Grampians Health ( Site 1802), Ballarat, Victoria

Royal Perth Hospital-Haematology ( Site 1801), Perth, Western Australia

Hospital Erasto Gaertner ( Site 2302), Curitiba, Parana

Liga Norte Riograndense Contra o Câncer ( Site 2305), Natal, Rio Grande Do Norte

Princess Margaret Cancer Centre-Division of Medical Oncology and Hematology ( Site 0200), Toronto, Ontario

Biocenter ( Site 2401), Concepcion., Biobio

IC La Serena Research ( Site 2405), La Serena, Coquimbo

Oncocentro Valdivia ( Site 2407), Valdivia., Los Rios

Clínica Inmunocel ( Site 2404), Santiago, Region M. De Santiago

Clínica RedSalud Vitacura ( Site 2409), Santiago, Region M. De Santiago

Bradfordhill ( Site 2403), Santiago, Region M. De Santiago

Beijing Cancer hospital ( Site 3000), Beijing, Beijing

Chongqing University Cancer Hospital-Medical Oncology ( Site 3025), Chongqing, Chongqing

Chongqing University Three Gorges Hospital ( Site 3026), Chongqing, Chongqing

Sun Yat-sen University Cancer Center-Internal Medicine ( Site 3001), Guangzhou, Guangdong

Zhujiang Hospital ( Site 3002), Guangzhou, Guangdong

The First Affiliated Hospital of Henan University of Science &Technology ( Site 3029), Luoyang, Henan

Henan Cancer Hospital-hematology department ( Site 3013), Zhengzhou, Henan

Union Hospital Tongji Medical College Huazhong University of Science and Technology ( Site 3017), Wuhan, Hubei

The First Affiliated Hospital of Nanchang University ( Site 3004), Nanchang, Jiangxi

Jiangxi Provincial Cancer Hospital ( Site 3005), Nanchang, Jiangxi

The First Hospital of Jilin University-Hematology ( Site 3012), Changchun, Jilin

Fudan University Shanghai Cancer Center ( Site 3009), Shanghai, Shanghai

West China Hospital of Sichuan University-Head and Neck Oncology ( Site 3016), Cheng Du, Sichuan

Sichuan Cancer hospital-Oncology ( Site 3021), Chengdu, Sichuan

Zhejiang Cancer Hospital ( Site 3014), Hangzhou, Zhejiang

The First Affiliated Hospital Zhejiang University School of Medicine ( Site 3027), Hangzhou, Zhejiang

Hospital Pablo Tobon Uribe ( Site 0804), Medellin, Antioquia

Instituto Médico de Alta Tecnologia S.A.S ( Site 0803), Monteria, Cordoba

FUNDACION CTIC CENTRO DE TRATAMIENTO E INVESTIGACION SOBRE CANCER LUIS CARLOS SARMIENTO ANGULO ( Site 0801), Bogota, Distrito Capital De Bogota

Oncologos del Occidente ( Site 0800), Pereira., Risaralda

Fundacion Valle del Lili ( Site 0802), Cali, Valle Del Cauca

Hospital Metropolitano - Sede Lindora ( Site 2500), Santa Ana, San Jose

CIMCA ( Site 2501), San Jose, Not set

centre hospitalier lyon sud-Service Hématologie ( Site 0702), Pierre-Bénite, Rhone

Pitie Salpetriere University Hospital-Clinical haematology ( Site 0700), Paris, Not set

University Hospital of Alexandroupolis ( Site 0903), Alexandroupolis, Anatoliki Makedonia Kai Thraki

Evangelismos General Hospital of Athens ( Site 0900), Athens, Attiki

Regional General Hospital of Athens "Laiko" ( Site 0901), Athens, Attiki

MEDI-K ( Site 2602), Guatemala, Not set

Private Practice- Dr. Rixci Augusto Lenin Ramírez ( Site 2601), Guatemala, Not set

CELAN,S.A ( Site 2603), Guatemala, Not set

Queen Mary Hospital ( Site 3100), Hong Kong, Not set

Princess Margaret Hospital ( Site 3101), Hong Kong, Not set

Emek Medical Center-Hematology Unit ( Site 1102), Afula, Not set

Carmel Hospital ( Site 1103), Haifa, Not set

Hadassah Medical Center ( Site 1100), Jerusalem, Not set

Humanitas-U.O di Oncologia medica ed Ematologia ( Site 1203), Rozzano, Milano

IRCCS - AOU di Bologna-Istituto di Ematologia "L. e A. Seragnoli" ( Site 1200), Bologna, Not set

Istituto Nazionale Tumori IRCCS Fondazione Pascale ( Site 1202), Napoli, Not set

Fondazione Policlinico Universitario Agostino Gemelli IRCCS -ISTITUTO DI EMATOLOGIA ( Site 1204), Roma, Not set

Seoul National University Hospital-Oncology ( Site 0302), Seoul, Not set

Samsung Medical Center ( Site 0300), Seoul, Not set

Aotearoa Clinical Trials ( Site 0501), Auckland, Not set

Clínicas AUNA Sede Chiclayo ( Site 2803), Chiclayo, Lambayeque

Clínica San Felipe ( Site 2805), Lima, Not set

Specjalistyczny Szpital im. Dr Alfreda Sokolowskiego w Walbrzychu ( Site 1305), Walbrzych, Dolnoslaskie

Uniwersytecki Szpital Kliniczny-Klinika Hematologii, Nowotworow Krwi i Transplantacji Szpiku ( Site 1301), Wroclaw, Dolnoslaskie

Centrum Onkologii Ziemi Lubelskiej-Oddzial Hematologii i Transplantacji Szpiku ( Site 1304), Lublin, Lubelskie

Pratia MCM Krakow ( Site 1303), Krakow, Malopolskie

Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Nowotworów Układu Chłonnego ( Site 1300), Warszawa, Mazowieckie

Szpitale Pomorskie Sp. z o. o.-Hematology and Bone Marrow Transplantation Department ( Site 1302), Gdynia, Pomorskie

Wojewódzki Szpital Specjalistyczny im. J. Korczaka w Słupsku ( Site 1309), Słupsk, Pomorskie

Pratia Onkologia Katowice ( Site 1306), Katowice, Slaskie

Faculty of Medicine Siriraj Hospital-Division of Hematology, Department of Medicine ( Site 0400), Bangkok, Krung Thep Maha Nakhon

Chulalongkorn University ( Site 0402), Pathumwan, Krung Thep Maha Nakhon

Maharaj Nakorn Chiang Mai Hospital ( Site 0401), Chiang Mai, Not set

Dr. Abdurrahman Yurtaslan Ankara Onkoloji Egitim ve Arastırma Hastanesi ( Site 1912), Yenimahalle, Ankara

Ege University Medicine of Faculty ( Site 1902), Bornova, Izmir

Ankara University Hospital Cebeci-hematology ( Site 1901), Ankara, Not set

Mega Medipol-Hematology ( Site 1909), Istanbul, Not set

Dokuz Eylül Üniversitesi-Hematology ( Site 1905), Izmir, Not set

Ondokuz Mayıs Universitesi ( Site 1907), Samsun, Not set

MNPE ClinCenter of Oncology,Hematology,Transplantology and Palliative Care of CherkasyRegCouncil ( Site 2000), Cherkasy, Cherkaska Oblast

Communal non-profit enterprise "Regional clinical hospital of Ivano-Frankivsk Regional Council" ( Site 2004), Ivano-Frankivsk, Ivano-Frankivska Oblast

Institute of Blood Pathology and Transfusion Medicine AMS Ukraine ( Site 2002), Lviv, Lvivska Oblast

State non-profit enterprise National Cancer Institute ( Site 2001), Kyiv, Not set

National Research Center for Radiation Medicine of National Academy of Medical Sciences of Ukraine ( Site 2005), Kyiv, Not set

Public Non-Profit Enterprise Kyiv City Clinical Hospital #9 under the Executive Body of Kyiv City Co ( Site 2003), Kyiv, Not set

Aberdeen Royal Infirmary ( Site 2104), Aberdeen, Aberdeen City

University College London Hospital-Cancer Clinical Trials Unit ( Site 2100), London-Camden, London, City Of

Conditions: DLBCL, Diffuse Large B-Cell Lymphoma

Learn More ›

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

NCT06395103

Recruiting

Substudy 01A is part of a platform study. The purpose of this study is to assess the efficacy and safety of zilovertamab vedotin in pediatric participants with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL), diffuse large B-cell lymphoma (DLBCL)/Burkitt lymphoma, or neuroblastoma and in pediatric and young adult participants with Ewing sarcoma.

Gender:

ALL

Ages:

Between 6 months and 25 years

Trial Updated:

05/28/2025

Locations: Children's Hospital Los Angeles ( Site 1006), Los Angeles, California +52 locations

Children's Hospital Los Angeles ( Site 1006), Los Angeles, California

Children's Hospital Colorado-Center for Cancer and Blood Disorders ( Site 1016), Aurora, Colorado

Yale-New Haven Hospital ( Site 1012), New Haven, Connecticut

Johns Hopkins All Children's Hospital ( Site 1025), Saint Petersburg, Florida

University of Iowa-Holden Comprehensive Cancer Center ( Site 1017), Iowa City, Iowa

Dana-Farber Cancer Institute ( Site 1013), Boston, Massachusetts

Corewell Health ( Site 1001), Grand Rapids, Michigan

Children's Mercy Hospital ( Site 1024), Kansas City, Missouri

Rutgers Cancer Institute of New Jersey ( Site 1008), New Brunswick, New Jersey

New York Medical College ( Site 1023), Valhalla, New York

Sanford Fargo Medical Center-Roger Maris Cancer Center ( Site 1003), Fargo, North Dakota

Oregon Health and Science University ( Site 1004), Portland, Oregon

Children's Hospital of Philadelphia (CHOP) ( Site 1021), Philadelphia, Pennsylvania

Sanford Children's Hospital-Sanford Children's Specialty Clinic ( Site 1015), Sioux Falls, South Dakota

University of Texas MD Anderson Cancer Center ( Site 1007), Houston, Texas

Intermountain - Primary Children's Hospital ( Site 1014), Salt Lake City, Utah

Sydney Children's Hospital-Kids Cancer Centre ( Site 1997), Randwick, New South Wales

Queensland Children's Hospital-Oncology & Haematology ( Site 1996), Brisbane, Queensland

UZ Gent ( Site 1428), Gent, Oost-Vlaanderen

Hospital Erasto Gaertner-CEPEP - Pesquisa Clínica ( Site 1268), Curitiba, Parana

Hospital de Clinicas de Porto Alegre ( Site 1265), Porto Alegre, Rio Grande Do Sul

Fundação Pio XII - Hospital de Câncer de Barretos ( Site 1264), Barretos, Sao Paulo

Fundação Faculdade Regional de Medicina de São José do Rio Preto-Centro Integrado de Pesquisa ( Site 1267), São José do Rio Preto, Sao Paulo

Hospital Carlos Van Buren ( Site 1880), Valparaíso, Valparaiso

Hospital Pablo Tobon Uribe ( Site 1923), Medellin, Antioquia

Clinica de la Costa S.A.S.-Clinical Research Oncology & Hematology -Pediatric ( Site 1924), Barranquilla, Atlantico

IMAT S.A.S ( Site 1921), Monteria, Cordoba

Rigshospitalet-Department of paediatrics and adolescent medicine, Section of Paed haem-onc ( Site 1467), Copenhagen, Hovedstaden

CHU de Bordeaux. Hopital Pellegrin ( Site 1105), Bordeaux, Aquitaine

Gustave Roussy ( Site 1103), Villejuif, Ile-de-France

Centre Hospitalier Universitaire de Nantes - Hôpital Femme-Enfant-Adolescent Chu De Nantes ( Site 1104), Nantes, Pays-de-la-Loire

CENTRE LEON BERARD-IHOPE (pediatrric oncology) ( Site 1100), Lyon, Rhone-Alpes

Universitätsklinikum Münster - Albert Schweitzer Campus-Pädiatrische Hämatologie und Onkologie ( Site 1141), Münster, Nordrhein-Westfalen

Aghia Sophia Children's Hospital-First Department of Pediatrics, National and Kapodistrian Universi ( Site 1797), Athens, Attiki

Semmelweis Egyetem ( Site 1838), Budapest, Not set

Rambam Health Care Campus-Pediatric Hemato-Oncology ( Site 1674), Haifa, Not set

Sheba Medical Center ( Site 1675), Ramat Gan, Not set

Fondazione IRCCS Istituto Nazionale dei Tumori-Pediatric Oncology ( Site 1552), Milan, Lombardia

Ospedale Pediatrico Bambino Gesù IRCCS-Dipartimento di Onco-Ematologia e Terapia Cellulare e Genica ( Site 1553), Rome, Roma

Seoul National University Hospital-Pediatrics ( Site 1972), Seoul, Not set

Asan Medical Center-Pediatrics - Pedicatric Oncology ( Site 1973), Seoul, Not set

Prinses Maxima Centrum voor Kinderoncologie ( Site 1510), Utrecht, Not set

Hospital Sant Joan de Déu-Pediatric Oncology Department ( Site 1717), Esplugas De Llobregat, Barcelona

Hospital Infantil Universitario Niño Jesús-Servicio de Onco-Hematología Pediátrica ( Site 1715), Madrid, Madrid, Comunidad De

Hospital Universitari Vall d'Hebron-Servei de Hematologia i Oncologia Pediatrica ( Site 1716), Barcelona, Not set

Prövningsenhet barn, Sahlgrenska Universitetssjukhuset ( Site 1634), Gothenburg, Vastra Gotalands Lan

National Taiwan University Hospital ( Site 1983), Taipei, Not set

Hacettepe Universite Hastaneleri ( Site 1961), Ankara, Not set

Ankara Bilkent Şehir Hastanesi ( Site 1962), Ankara, Not set

Ege Universitesi Hastanesi ( Site 1963), İzmir, Not set

Royal Victoria Infirmary-Great North Children's Hospital ( Site 1348), Newcastle upon Tyne, England

University College London Hospital ( Site 1350), London, London, City Of

University Hospital of Wales ( Site 1346), Cardiff, Not set

Conditions: B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma, Burkitt Lymphoma, Neuroblastoma, Ewing Sarcoma

Learn More ›

Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+

NCT06846463

Recruiting

This study is a single-arm, open label, non-randomized, phase 2 trial of zanubrutinib in patients with diffuse large B-cell lymphoma (DLBCL) who have an MYD88 L265P mutation, a CD79B mutation, a NOTCH1 truncation, or who are CD5+ by immunohistochemistry (IHC).

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/27/2025

Locations: Virginia Commonwealth University, Richmond, Virginia

Conditions: Diffuse Large B-cell Lymphoma, DLBCL - Diffuse Large B Cell Lymphoma

Learn More ›

Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL

NCT05952024

Recruiting

The study will measure the safety, tolerability, and efficacy with acalabrutinib in combination with rituximab in treatment-naïve elderly and/or frail patients with diffuse large B-cell lymphoma (DLBCL), who are otherwise unsuitable for standard front line chemoimmunotherapy treatments.

Gender:

ALL

Ages:

Between 65 years and 99 years

Trial Updated:

05/26/2025

Locations: Research Site, La Jolla, California +51 locations

Research Site, La Jolla, California

Research Site, Orange, California

Research Site, Stamford, Connecticut

Research Site, Jacksonville, Florida

Research Site, Des Moines, Iowa

Research Site, Lexington, Kentucky

Research Site, Beltsville, Maryland

Research Site, Towson, Maryland

Research Site, Detroit, Michigan

Research Site, Sioux Falls, South Dakota

Research Site, Lubbock, Texas

Research Site, Olympia, Washington

Research Site, Tacoma, Washington

Research Site, Barretos, Not set

Research Site, Belo Horizonte, Not set

Research Site, Brasilia, Not set

Research Site, Campinas, Not set

Research Site, Curitiba, Not set

Research Site, Florianópolis, Not set

Research Site, Goiania, Not set

Research Site, Natal, Not set

Research Site, Porto Alegre, Not set

Research Site, Recife, Not set

Research Site, Ribeirão Preto, Not set

Research Site, Rio de Janeiro, Not set

Research Site, Sao Luis, Not set

Research Site, Sao Paulo, Not set

Research Site, Sorocaba, Not set

Research Site, São José do Rio Preto, Not set

Research Site, São Paulo, Not set

Research Site, Busan, Not set

Research Site, Daegu, Not set

Research Site, Gyeongsangnam-do, Not set

Research Site, Incheon, Not set

Research Site, Jeonju-si, Not set

Research Site, Seo-gu, Not set

Research Site, Seoul, Not set

Research Site, Suwon-si, Not set

Research Site, Ulsan, Not set

Research Site, San Juan, Not set

Conditions: Diffuse Large B-Cell Lymphoma

Learn More ›

A Study to Evaluate the Pharmacokinetics and Safety of Loncastuximab Tesirine in Participants With Relapsed or Refractory Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma With Hepatic Impairment (LOTIS-10)

NCT05660395

Recruiting

The primary objective of this study is to determine the recommended dosing regimen of loncastuximab tesirine in diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBCL) participants with moderate and severe hepatic impairment.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/22/2025

Locations: The Oncology Institute of Hope & Innovation - Lynwood, Lynwood, California +13 locations

Conditions: Diffuse Large B-Cell Lymphoma, High-grade B-cell Lymphoma

Learn More ›

1 - 12 of 35